外周血CK19mRNA表达与乳腺癌微转移的相关性研究

Association of peripheral CK19 mRNA expression with micrometastasis in patients with breast carcinoma

目的检测乳腺癌患者外周血中细胞角蛋白19（cytokeratin 19，CKl9）mRNA的表达，探讨其表达是否可作为判断乳腺癌外周血微转移及预后的分子生物学指标。方法采用逆转录一多聚酶链反应（reverse transcription polymerase chain reaction，RT—PCR）技术检测75例乳腺癌患者、21例乳腺良性病变患者和20例健康者外周血中CKl9mRNA的表达情况。结果CKl9mRNA在乳腺癌患者、乳腺良性病变患者和健康者血清中阳性率分别为36％、0％和0％。乳腺癌患者和乳腺良性肿瘤患者及健康者血清中CKl9mRNA表达阳性率差异有统计学上的意义（P〈0．05）。CKl9mRNA表达阳性率和临床分期呈正相关（P〈0．05）。结论乳腺癌患者外周血中CKl9mRNA表达与临床分期密切相关，提示该项指标有望预测乳腺癌外周血微转移和判断预后。

Objective To detect the expression of CKI9 mRNA in peripheral blood in patients with breast carcinoma and to explore whether this expression can be used as a molecular biological marker for predicting micrometastasis and prognosis. Methods Peripheral serum samples were collected from 75 patients with breast carcinoma, 21 patients with benign breast lesions, and 20 healthy subjects. Expression of CK19 mRNA was detected by RT-PCR. Results The positive rate of CK19 mRNA was 36.0% in patients with breast carcinoma and 0% in those with benign breast lesions and in healthy subjects; and there were significant differences in the expression of CK19 mRNA among patients with breast carcinoma, those with benign breast lesions, and healthy subjects （P〈0.001）. The positive rate of CK19 mRNA positively correlated with the clinical stages （P〈0.05）. Conclusions CK19 mRNA can be detected in peripheral serum of breast carcinoma patients. CK19 mRNA expression closely correlates with the clinical stages in patients with breast carcinoma, suggesting this index can be used to predict micrometastasis and prognosis.